Latest revenue
—
as of 2025-12-31
Latest net income
$-12.6M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think APRE is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $9.3M
- Enterprise value
- $-37.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.22×
- Dividend yield
- 0.0%
- 52-wk high
- $2.22
- 52-wk low
- $0.55
- Beta
- —
- Shares out
- 12.4M
5-year trend
What this company does
You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited financial information and notes thereto included in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, including forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report, our actual results could differ materially from the results…
AI summary unavailable — showing raw filing excerpt
Generated from APRE's filing dated 2019-11-14
Key risks
Item 1A. Risk Factors Our business is subject to substantial risks and uncertainties. Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors below together with the information contained elsewhere in this Annual Report on Form 10-K, including Part II, Item 8 “Financial Statements and Supplementary Data” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our other public filings in evaluating our business. Any of the risks and uncertainties described below and in our other filings with the SEC, either alone or taken together, could materially and adversely affect our…
AI summary unavailable — showing raw filing excerpt
Generated from APRE's filing dated 2019-11-14
Profitability
Return on equity
-101.3%
50.9%Return on assets
-79.1%
46.3%Leverage
Debt / equity
0.28×
16.0%Debt / assets
21.9%
12.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-3.3M | +16.4% | — |
Q4 2025 2025-12-31 | — | — | $-2.5M | +15.2% | — |
Q3 2025 2025-09-30 | — | — | $-3.0M | +21.4% | — |
Q2 2025 2025-06-30 | — | — | $-3.2M | +6.7% | — |
Q1 2025 2025-03-31 | — | — | $-3.9M | -39.9% | — |
Q4 2024 2024-12-31 | — | — | $-2.9M | — | — |
Q3 2024 2024-09-30 | — | — | $-3.8M | -18.1% | — |
Q2 2024 2024-06-30 | — | — | $-3.5M | -6.5% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on APRE — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$210.9K
Insider selling
$0
Net activity
+$210.9K
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns APRE
Institutional value
$884.8K
Total shares held
1.2M
Distinct holders
11
-10 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 1.0M | $774.8K | +645.0K (+174.1%) | Added |
| 2 | BNP PARIBAS FINANCIAL MARKETS | 39.8K | $30.4K | +12.5K (+45.7%) | Added |
| 3 | VANGUARD FIDUCIARY TRUST CO | 38.5K | $29.3K | — | New |
| 4 | LPL Financial LLC | 21.1K | $16.1K | -5.0K (-19.2%) | Trimmed |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 19.6K | $15.0K | — | New |
| 6 | HighTower Advisors, LLC | 13.9K | $10.6K | +0 (+0.0%) | No change |
| 7 | BlackRock, Inc. | 8.5K | $6.5K | +0 (+0.0%) | No change |
| 8 | UBS Group AG | 2.2K | $1.6K | -308 (-12.5%) | Trimmed |
| 9 | GROUP ONE TRADING LLC | 577 | $440 | +0 (+0.0%) | No change |
| 10 | WealthCollab, LLC | 158 | $121 | +0 (+0.0%) | No change |
| 11 | SBI Securities Co., Ltd. | 16 | $12 | +1 (+6.7%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once APRE's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.